![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, December 10, 2014 12:32:39 PM
Patience is needed. One must not set expectations beyond what is rational.
They are where they are. Great progress is being made. We'll get more guidance from them in January.
NDA and/or relationship with Merck might preclude Punit talking about partnerships. In fact, I see Merck potentially buying ONCS at some point, depending how the P2b results are.
I'll reserve judgement until we start to see some P2b data. Until then, I'm perfectly happy being long in ONCS and other biotechs in my portfolio. It's a great space to be in oncology, with room for quite a few companies, including ONCS.
Folks, at this point it's all about the P2b data, and little else. Build it, and they will come.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM